Despite the fact that the number of diagnosed cases of malignant mesothelioma are expected to rise in the next decades, there has been little real progress in available treatments, and the chemotherapy drug used to treat the disease is the same one that has been used for the last several  years. Though there is a natural push for new drugs to be brought to the market more quickly, Dr Richard Knight of ApconiX says ‘There’s a need for a change in attitude among researchers, and that there needs to be a greater emphasis for safety in the earliest stages of drug development rather than in the end stages’.

Read more here: Cancer Drug Developer Says Safety Must be Prioritized in Drugs for Cancers, Including Mesothelioma